| Market Cap | 2.85B | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -3.99M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 4.00% |
| Sales | 239.72M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 5.00% |
| Dividend | N/A | Price/Book | 1.08 | EPS next 5Y | - | 52W High Chg | -22.00% |
| Recommedations | - | Quick Ratio | 8.76 | Shares Outstanding | 65.90M | 52W Low Chg | 22.00% |
| Insider Own | 25.36% | ROA | -1.11% | Shares Float | 44.54M | Beta | 0.02 |
| Inst Own | 34.94% | ROE | -0.15% | Shares Shorted/Prior | -/- | Price | 41.75 |
| Gross Margin | -0.66% | Profit Margin | 88.31% | Avg. Volume | 83 | Target Price | - |
| Oper. Margin | -33.63% | Earnings Date | - | Volume | 150 | Change | 0.00% |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.